Compare Annaly Capital Management, Inc. (NLY) vs 10X Genomics Inc (TXG) Price & Performance

NLY trades at $17.93, down 2.66% on the day, amid a bearish technical signal despite a low P/E of 4.33 and P/B of 0.89 suggesting undervaluation. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Strong profitability metrics include a net income margin of 92.77% and ROE of 20.66%. Recent news highlights its high dividend yield near 15% and portfolio expansion, though the stock faces pressure from rising mortgage rates and a negative cash flow from investing activities of -$27.36 billion in 2025.

The outlook is mixed: attractive valuation and consistent earnings beats support upside to the $22.00 consensus price target, but high leverage (debt-to-asset ratio of 23.55 in 2025) and interest rate sensitivity pose significant risks. Investors are compensated with a robust dividend, yet the stock's recent decline reflects concerns over macroeconomic headwinds impacting mortgage REITs.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.